Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$38.20 USD

38.20
914,439

-0.95 (-2.43%)

Updated Sep 29, 2023 04:00 PM ET

After-Market: $38.21 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.17%
2Buy17.86%
3Hold9.20%
4Sell5.01%
5Strong Sell2.50%
S&P50010.82%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for HALO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Halozyme Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Assets          
Cash & Equivalents 363 741 368 421 355
Receivables 231 91 98 59 30
Notes Receivable 0 0 0 0 0
Inventories 100 54 61 29 23
Other Current Assets 45 40 28 33 21
Total Current Assets 739 926 555 543 428
Net Property & Equipment 76 9 11 11 7
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 44 155 0 0 0
Intangibles 956 0 0 0 0
Deposits & Other Assets 27 14 15 12 5
Total Assets 1,842 1,104 580 566 440
Liabilities & Shareholders Equity 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Notes Payable 0 0 0 0 0
Accounts Payable 18 2 2 6 4
Current Portion Long-Term Debt 13 89 397 20 92
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 97 24 20 56 50
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 3 2 2 4 4
Total Current Liabilities 131 117 421 86 149
Mortgages 0 0 0 0 0
Deferred Taxes/Income 2 3 4 1 5
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,493 787 0 383 35
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 46 1 3 4 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,672 907 429 474 191
Shareholders Equity 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 27 256 625 695 780
Retained Earnings 143 -59 -475 -604 -531
Other Equity -1 -1 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 170 197 151 92 249
Total Liabilities & Shareholder's Equity 1,842 1,104 580 566 440
Total Common Equity 170 197 151 92 249
Shares Outstanding 135.20 140.70 135.10 146.50 144.50
Book Value Per Share 1.26 1.40 1.12 0.63 1.72

Fiscal Year End for Halozyme Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Assets          
Cash & Equivalents 348 276 363 266 209
Receivables 246 195 231 233 189
Notes Receivable 0 0 0 0 0
Inventories 132 108 100 103 98
Other Current Assets 39 37 45 51 46
Total Current Assets 766 615 739 653 542
Net Property & Equipment 75 78 76 37 37
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 24 36 44 0 0
Intangibles 928 945 956 1,148 1,176
Deposits & Other Assets 18 26 27 26 27
Total Assets 1,810 1,699 1,842 1,865 1,781
Liabilities & Shareholders Equity 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Notes Payable 0 0 0 0 0
Accounts Payable 10 9 18 18 12
Current Portion Long-Term Debt 0 0 13 13 99
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 105 80 97 74 84
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1 3 3 4 4
Total Current Liabilities 116 92 131 109 200
Mortgages 0 0 0 0 0
Deferred Taxes/Income 2 2 2 32 6
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,496 1,494 1,493 1,491 1,147
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 45 46 135 136
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,659 1,634 1,672 1,768 1,488
Shareholders Equity 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 12 0 27 13 271
Retained Earnings 140 66 143 86 24
Other Equity -2 0 -1 -2 -2
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 151 66 170 97 293
Total Liabilities & Shareholder's Equity 1,810 1,699 1,842 1,865 1,781
Total Common Equity 151 66 170 97 293
Shares Outstanding 131.60 131.60 135.20 137.70 137.90
Book Value Per Share 1.15 0.50 1.26 0.70 2.13